TY - T1的性别差异在尿酸盐的安全设计和结果在PD (SURE-PD)审判JF -神经学乔-神经病学SP - e1328 LP - - 10.1212 / WNL e1338做。首页0000000000008194六世- 93 - 14盟——迈克尔·a·史瓦西AU -埃里克·a·Macklin盟Rachit问题非盟-经济部Battacharyya盟-罗伯特·洛根盟-阿尔贝托·j·Espay盟-阿尔伯特·y挂盟恩典Bwala AU -克里斯托弗·g·Goetz盟David s .罗素盟——约翰·l·Goudreau盟与a Parashos AU -玛丽·h·Saint-Hilaire AU -爱丽丝鲁道夫盟约书亚m .兔子盟-加里·卡兰医师c . AU - Alberto Ascherio博士盟代表帕金森研究小组SURE-PD调查员Y1 - 2019/10/01 UR - //www.ez-admanager.com/content/93/14/e1328.abstract N2 -目的探讨是否在帕金森病(PD)男性和女性有不同的生化和临床反应与肌苷长期治疗。首页方法安全的尿酸盐在帕金森病(SURE-PD)审判招收了75名患有早期PD和基线血清尿酸盐低于6 mg / dL,随机3双盲治疗武器:口服安慰剂或肌苷滴定产生轻度(6.1 - -7.0 mg / dL)或中度(7.1 - -8.0 mg / dL)血清尿酸盐海拔2年。帕金森症、血清尿酸盐和血浆抗氧化能力测定基线和反复治疗;CSF尿酸盐是评估一次,3个月。在二次分析结果按性别分层。结果肌苷生产的绝对增加平均血清尿酸盐从基线为50% (3.0 mg / dL)的女性比男性(2.0 mg / dL),符合预期的基线水平较低的女性。同样,只有女性CSF尿酸盐明显更大的轻度或中度肌苷(+ 87% [p & lt;0.001)+ 98% (p & lt;分别为0.001])比安慰剂(相比男人:+ 10% (p = 0.6), + 14% (p = 0.4),分别)。女性肌苷高剂量组显示7.0统一帕金森病评定量表(UPDRS)点/年降低,下降的速度与安慰剂(p = 0.01)。 In women, slower rates of UPDRS change were associated with greater increases in serum urate (r = −0.52; p = 0.001), and with greater increases in plasma antioxidant capacity (r = −0.44; p = 0.006). No significant associations were observed in men.Conclusions Inosine produced greater increases in serum and CSF urate in women compared to men in the SURE-PD trial, consistent with the study's design and with preliminary evidence for slower clinical decline in early PD among women treated with urate-elevating doses of inosine.Clinicaltrials.gov identifier NCT00833690.Classification of evidence This study provides Class II evidence that inosine produced greater urate elevation in women than men and may slow PD progression in women.AE=adverse event; ANOVA=analysis of variance; CI=confidence interval; FRAP=ferric reducing antioxidant power; MAO-B=monoamine oxidase-B; PD=Parkinson disease; SAE=serious adverse event; SURE-PD=Safety of Urate Elevation in Parkinson’s Disease; UPDRS=Unified Parkinson’s Disease Rating Scale ER -